Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors December 10, 2024
Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive NMIBC December 10, 2024
Relay Therapeutics & Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors December 10, 2024
DSMB recommends continuation of Ph 3 study of Bria-IMT™ + an immune checkpoint inhibitor in metastatic breast cancer patients December 10, 2024
Ph 3 POD1UM-304 trial of Retifanlimab (Zynyz®) + Chemo met primary endpoint of OS and all secondary endpoints in patients with 1L metastatic NSCLC December 10, 2024
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated NSCLC December 10, 2024
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials December 10, 2024
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target December 10, 2024
Doses Selected for Ph 1b Expansion Trials Supported by Efficacy & Safety Profile Observed in Ph 1a Dose Escalation for JANX007 in metastatic CRPC December 10, 2024
First Patient Enrolled in Taiwan for Ph 2 HARMONIC™ Trial of LP-300 in Never-Smoker NSCLC Patients December 10, 2024
First Patient Dosed in Ph 3 Clinical trial of HLX22/AC101 in 1L HER2-positive advanced gastric/GEJ cancer December 10, 2024
Datopotamab Deruxtecan and Datopotamab Deruxtecan + Durvalumab Arms completed in the I-SPY2 Trial for Stage 2/3 Neoadjuvant Breast Cancer December 10, 2024
Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC December 10, 2024
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFRMutated NSCLC in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis December 10, 2024
Long-Term Follow-up Study to the OLYMPUS Trial Reports Median Duration of Response of 4 Years in Patients Who Achieved a Complete Response with JELMYTO® December 10, 2024
Positive Results Announced from Ph 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC December 10, 2024
FAILED TRIAL: Ph 3 KEYLYNK-001 Trial Met Primary Endpoint of PFS, but not OS, in Patients With Advanced Epithelial Ovarian Cancer December 10, 2024
Blenrep (belantamab mafodotin) combination accepted for priority review in China in R/R multiple myeloma December 10, 2024
Regulatory Update Related to Supplemental NDA for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced NETs provided December 10, 2024
